Psoriasis: updated guidelines on use of biologics

Access to the full content of this site is available only to registered healthcare professionals. Register to read more
  • The British Association of Dermatologist (BAD) has issued 2017 guidelines updating information on evidence-based recommendations on the use of biologic therapies in adults and children with psoriasis.
Why this matters
  • This guideline updates previous guidelines, addressing areas of major change in the evidence base or clinical practice.
Study design
  • The guideline development group included dermatologists, pediatric dermatologists, rheumatologists, virologists, and obstetricians using BAD guidelines.
  • Guidelines are relevant to use of adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade), ixekizumab (Taltz), secukinumab (Cosentyx), and ustekinumab (Stelara).
  • Funding: None disclosed. 
Key results
  • Strong evidence for caution prescribing biologics to people with a history of cancer and at risk for skin cancer.
  • Strong evi...